Abstract

The pace of technological innovation in healthcare has accelerated dramatically, fueled by advances in artificial intelligence (AI), software as a medical device and digitally-enabled drug discovery. Regulatory systems, historically designed for static products and linear development pathways, have had to adapt in response.

This article explores the shift from traditional, premarket-focused approval models toward more dynamic, lifecycle-based regulatory oversight. It challenges the perception of regulation as a barrier to innovation and instead highlights a risk-based regulatory approach supported by adaptive tools, such as real-world evidence frameworks, regulatory sandboxes and predetermined change control mechanisms. Drawing on examples from AI-driven diagnostics, in silico methods, drug discovery and medical device development tools, the article illustrates how regulators are increasingly acting as collaborators, balancing uncertainty, benefit and risk in an era of continuous technological evolution.